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ABSTRACT
Syndesmos (SDOS) is a functionally poorly char-
acterized protein that directly interacts with p53
binding protein 1 (53BP1) and regulates its recruit-
ment to chromatin. We show here that SDOS in-
teracts with another important cancer-linked pro-
tein, the chaperone TRAP1, associates with actively
translating polyribosomes and represses transla-
tion. Moreover, we demonstrate that SDOS directly
binds RNA in living cells. Combining individual gene
expression profiling, nucleotide crosslinking and im-
munoprecipitation (iCLIP), and ribosome profiling,
we discover several crucial pathways regulated post-
transcriptionally by SDOS. Among them, we identify
a small subset of mRNAs responsible for the biogen-
esis of primary cilium that have been linked to devel-
opmental and degenerative diseases, known as cil-
iopathies, and cancer. We discover that SDOS binds
and regulates the translation of several of these mR-
NAs, controlling cilia development.
INTRODUCTION
Protein Syndesmos (SDOS, also called NUDT16L1 and
TIRR) is a paralog of the nuclear decapping enzyme
NUDT16. Having likely emerged by gene duplication,
SDOS diverged from its ancestor by losing its de-
capping activity through critical sequence alterations
within the catalytic NUDIX domain. In particular, a re-
peated glycine/leucine sequence replaced the glutamic acid
residues required for catalytic activity of the NUDIX do-
main (1). Initially reported to promote the assembly of fo-
cal adhesions and actin stress fibers through its interaction
with Syndecan 4, Paxillin and its homologHic-5 (2,3), it has
recently been demonstrated that SDOS is a critical regula-
tor of the double strand break (DSB) repair pathway (4).
In absence of DNA damage, SDOS hijacks the component
of the DSB machinery 53BP1. Upon DSB, 53BP1 is phos-
phorylated by the ataxia telangiectasia-mutated (ATM) ki-
nase, promoting the interaction with Rap1-interacting fac-
tor 1 homolog (RIF-1) and the release of SDOS. In ab-
sence of SDOS, 53BP1 is recruited to chromatin (4). Over-
expression of SDOS hampers the recruitment of 53BP1 to
DSBs, whereas its silencing stimulates the DNA-damage-
dependent association of 53BP1 with RIF-1 or PTIP (4).
In addition to its nuclear localization, SDOS has been re-
ported to be present in the cytoplasm (2,3), although its role
in this subcellular location is unknown. Our data indicate
that SDOS interacts with the molecular chaperone TRAP1,
suggesting a functional interplay between these two pro-
teins. TRAP1 is a mainly mitochondrial member of the
HSP90 family, whose roles in cancer cell metabolism have
been extensively characterized (5,6). Interestingly, TRAP1
also localizes to the outer side of the endoplasmic reticulum
(ER) membrane (7), and co-sediments with actively trans-
lating ribosomes, invoking potential roles in mRNA trans-
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lation (8). TRAP1 silencing enhances the incorporation of
radiolabeled amino acids and sensitizes cells to drugs target-
ing protein synthesis (8). Furthermore, loss of TRAP1 in-
creases the levels of active polysomes and induces the phos-
phorylation of translation initiation factors (9) through the
activation of the upstream AKT/p70S6K signaling path-
way (10). Herein, we report that SDOS is a novel RNA-
binding protein (RBP) that interacts with TRAP1 at the
ER. SDOS regulates mRNA translation, and controls a
group of mRNAs crucial for the biogenesis of the primary
cilium. Importantly, perturbation of SDOS affects cilia for-
mation.
MATERIALS AND METHODS
Cell culture
Human HCT116 colon carcinoma cells and human cer-
vical carcinoma HeLa cells were purchased from Ameri-
can Type Culture Collection (ATCC) and cultured in Mc-
Coy’s 5A medium (HCT116) and Dulbecco’s modified Ea-
gle’s medium (HeLa), supplemented with 10% fetal bovine
serum and 1.5 mmol/l glutamine. The authenticity of the
cell lines was verified at the beginning of the project by short
tandem repeat (STR) profiling, in accordance with ATCC
product description. Generation of the HeLa Flp In TRex
stable cell lines expressing the eGFP-fusion proteins or the
short hairpin RNA was performed according to manufac-
turer’s protocol (Flp In TRex, Invitrogen) and cultured in
the presence of appropriate selective antibiotics. Addition
of tetracycline (1 g/ml) induces proteins as described in
(11).
Plasmid generation and transfection procedures
Full-length SDOS-myc cloned into pcDNA 3.1 myc-
his vector was obtained as previously described for
TRAP1-myc (7). To generate TRAP1-eGFP, SDOS-
eGFP and NUDT16-eGFP plasmids, HeLa cDNA
library and eGFP plasmid were used as templates for
fusion polymerase chain reaction (PCR). Resulting
chimeric cDNAs were cloned into pCDNA5/FRT/TO.
TRAP1-Flag-HA and SDOS-Flag-HA plasmids were
obtained in the same way by using the Flag-HA-tagged
vector. Inducible shRNAs were generated as described
in (12) (using BglII/KpnI as restriction sites in pFRT-
U6tetO vector). Short hairpin sequences used are:
GFP=agatctGCACAAGCTGGAGTACAACTACCTGA
CCCATAGTTGTACTCCAGCTTGTGCTTTTTggtacc;
SDOS=agatctGCCTCAGGATGCTCTTGTTTATCCT
GACCCAATAAACAAGAGCATCCTGAGGCTTTTTg
gtacc; TRAP1=agatctGCCCGGTCCCTGTACTCAGA
AACCTGACCCATTTCTGAGTACAGGGACCGGG
CTTTTTggtacc.
Transient transfection of DNA plasmids was performed
with the Polyfect TransfectionReagent (Qiagen: 301105) ac-
cording to the manufacturer’s protocol. TRAP1 and SDOS
transient silencing were performed with siRNAs purchased
from Qiagen (TRAP1: cat. no. SI00115150; SDOS: cat.
no. SI00713293). For control experiments, cells were trans-
fected with a similar amount of scrambled siRNA (Qia-
gen; cat. no. SI03650318). Transient transfections of siR-
NAswere performed usingHiPerFect TransfectionReagent
(Qiagen: 301704) according to the manufacturer’s protocol.
Protein–protein interaction identification by MS
1 × 15 cm plate of TRAP1-eGFP, SDOS-eGFP and un-
fused eGFP expressing cells was induced for 24 h with 1
g/ml of doxycycline. Cells were then lysed with 1 ml of ly-
sis buffer (NaCl 150mM, Tris–Hcl pH7.5 10mM, TritonX-
100 1%, MgCl2 5 mM, Dithiothreitol (DTT) 5 mM (fresh)
and AEBSF 1× (fresh)) on ice for 15 min. Lysates were
cleared by centrifugation at 16 000 × g for 5 min. Lysates
were precleared by incubation with 50 l of equilibrated
control agarose beads (Thermo Scientific) for 30 min at 4◦C
under gentle rotation. eGFP-fusion proteins were then cap-
tured from precleared lysates by incubation with 40 l of
GFP-Trap agarose beads (GFP-Trap A, Chromotek) per
milliliter of lysate for 2 h, 4◦C, gentle rotation. Beads were
collected by centrifugation and washed six times with lysis
buffer. During the second wash, samples were incubated at
37◦C for 5minwith 20g ofRNaseA (SigmaR4642). Sam-
ples were eluted from the beads by pH elution as indicated
in the manufacturer’s protocol (GFP-trap A; Chromotek).
Samples were prepared using the filter aided sam-
ple preparation. Briefly, Vivacon 500 filters (Sartorius,
VN01H02 10 kDa/VNCT01) were pre-washed with 200
l 0.1% trifluoroacetic acid in 50% acetone. Samples were
loaded to the filter and denatured with 200 l 8 M urea in
100 mM triethylammonium bicarbonate buffer (TEAB) for
30 min at room temperature. Denatured proteins were re-
duced by 10 mM tris (2-carboxyethyl) phosphine (TCEP)
for 30 min at room temperature and alkylated with 50 mM
chloroacetamide for 30 min at room temperature in the
dark. Subsequently, 1 g LysC (Wako) in 150 l 50 mM
TEAB containing 6 M urea was added and incubated at
37◦C for 4 h. Then the buffer was diluted to 2 M urea by 50
mM TEAB, followed by adding 0.5 g trypsin (Promega)
overnight at 37◦C. Trypsinized samples were centrifuged
and the flow-through containing peptides was dried and
re-suspended in 70 l 10% formic acid. Peptides were re-
suspended in 5% formic acid and 5% Dimethyl sulfox-
ide (DMSO) and then trapped on a C18 PepMap100 pre-
column (300 m i.d. × 5 mm, 100 A˚, Thermo Fisher Sci-
entific) using 0.1% formic acid in water at a pressure of
500 bar and analyzed on an Ultimate 3000 UHPLC sys-
tem (Thermo Fischer Scientific) coupled to a QExactive
mass spectrometer (Thermo Fischer Scientific). The pep-
tides were separated on an in-house packed analytical col-
umn (50 cm × 75 m i.d. packed with ReproSil-Pur 120
C18-AQ, 1.9 m, 120 A˚) and then electrosprayed directly
into an QExactive mass spectrometer (Thermo Fischer
Scientific) through an EASY-Spray nano-electrospray ion
source (Thermo Fischer Scientific) using a linear gradient
(length: 60 min, 7% to 28% solvent B (0.1% Formic acid in
acetonitrile), flow rate: 200 nl/min). The raw data were ac-
quired on the mass spectrometer in a data-dependent mode
(DDA). Full scanMS spectra were acquired in the Orbitrap
(scan range 350–2000 m/z, resolution 70000, AGC target
3xe6, maximum injection time 100 ms). After theMS scans,
the 20 most intense peaks were selected for high-energy col-
lision dissociation (HCD) fragmentation at 30% of normal-
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ized collision energy. HCD spectra were also acquired in the
Orbitrap (resolution 17 500,AGC target 5xe4,maximum in-
jection time 120 ms) with first fixed mass at 180 m/z. The
raw data files generated were processed using MaxQuant
(Version 1.5.0.35), integrated with the Andromeda search
engine as previously described. To identify protein groups,
peak lists were searched against mouse database as well as
list of common contaminants by Andromeda. Trypsin with
a maximum number of missed cleavages of two was cho-
sen. Acetylation (Protein N-term, i.e. only the n-terminus
of the protein), Oxidation (M) and Phosphorylation (S,
T and Y) were used as variable modifications while Car-
bamidomethylation (C) was set as a fixedmodification. Pro-
tein and post-translational modification (PTM) false dis-
covery rate were set at 0.01. Match between runs was ap-
plied.
In order to compare the sets of samples, the maxquant
output proteingroup text file was imported into the perseus
software package (Version 1.5.5.3) and the ‘Intensity’ for
each protein in all samples were subjected to a log2 trans-
formation. The statistical significance of protein enrich-
ment was assessed by a two-sided Student’s t-test within the
Perseus software package. Volcano plots were obtained by
plotting the log transformed P-value (-log10, Student’s t-
test) against the average fold change (log2).
Western blot and immunoprecipitation
Equal amounts of protein from cell lysates was subjected to
sodium dodecyl sulphate-polyacrylamide gel electrophore-
sis (SDS-PAGE) and transferred to a PVDF membrane
(Millipore). Protein immunoprecipitations were carried out
as previously described (9). eGFP-fusion proteins were im-
munoprecipitated with GFP-trap magnetic agarose beads
(GFP-trap MA, Chromotek) according to manufacturer’s
instructions. Where indicated, protein levels were quan-
tified by densitometric analysis using the software Im-
ageJ (13) using Actin as the internal control and assum-
ing the protein levels of the control equal 1. The follow-
ing antibodies were used for western blotting (WB), im-
munofluorescence and immunoprecipitation: anti-TRAP1
(sc-13557), anti--ACTIN (sc-69879), anti-GAPDH (sc-
69778), anti-BiP (sc-1051), anti VDAC1 (sc-8828), anti-
F1ATPase (sc-16690), anti-eGFP (sc-81045), anti-MYC
(sc-40), anti-VINCULIN (sc-73614), anti-PARP1 (sc-
25780), anti-eIF2 (sc-133132) from SantaCruz Biotech-
nology; anti-SDOS (HPA044186), anti-FLAG (FT425),
anti-TMEM107 (HPA052555) from Sigma-Aldrich; anti-
phosphoS6 ribosomal protein (#2215); anti-eIF4E (#2067),
anti-eIF4B (#3592), anti-phospho eIF2 (#3597) formCell
Signaling; anti-KIF7 (GTX130782) from Genetex; anti-
rpS28 (A305-095A) form Bethyl laboratories; anti-rpL3
was kindly provided by Prof. Giulia Russo, Department of
Pharmacy, University of Napoli ‘Federico II’.
Duolink in situ proximity ligation assay
Duolink in situ proximity ligation assay (Sigma-
Aldrich––DUO92101) was performed according to
the manufacturer’s instructions. Briefly, cells were seeded
on coverslips, fixed, permeabilized and hybridized with
primary antibodies. Cells were hybridized with secondary
antibodies conjugated with the PLA probes (PLUS and
MINUS), and then subjected to ligation and rolling circle
amplification using fluorescently labeled oligonucleotides.
Cells were washed and mounted on slides using a mounting
media with DAPI to detect nuclei and signal was detected
by confocal microscopy analysis.
Cell fractionation
Mitochondria and ER were purified by using the Qpro-
teomeMitochondria Isolation kit (Qiagen––37612) accord-
ing to the manufacturer’s protocol. For the collection of ri-
bosomal and non-ribosomal fractions, the lysates were cen-
trifuged at 10 000 × g at 4◦C for 15 min in order to remove
the mitochondria and cell debris. The supernatant was lay-
ered over a sucrose (20% wt/vol) cushion containing cyclo-
heximide and centrifuged at 149 000 × g for 2 h. The pellet
containing ribosomes and the upper and lower pellets of the
non-ribosomal supernatants were collected. The ribosomal
pellets were resuspended in the lysis buffer, after which im-
munoblotting was performed. Nuclear fractions were puri-
fied according to the manufacturer’s protocol (Abcam).
Polysome profiling
3 × 10 cm plates of cells were incubated either 15 min at
37◦C with fresh medium supplemented with 100 g/ml of
cycloheximide (Sigma) or 5 min at 37◦C with fresh medium
supplemented with 100 g/ml of puromycin (Sigma). Cells
were then washed with ice cold phosphate-buffered saline
(PBS) supplemented with 100 g/ml cycloheximide and re-
suspended in 1ml lysis buffer (10 mMTris–HCl pH 7.4, 100
mM KCl, 10 mM MgCl2, 1% Triton-X100, 2 U/ml Turbo
DNase (Ambion), 2 mM DTT, 10 U/ml Ribolock (Invit-
rogen), 100 g/ml of cycloheximide). Glass beads (Sigma-
Aldrich; G8772) were added to the lysate and cells were bro-
ken by vortexing at medium speed for 3 pulses of 10 s. After
5 min of incubation on ice, cell lysate was centrifuged for
5 min at 5000 rpm at 4◦C. The supernatant was collected,
and the absorbance was measured at 260 nm with the Nan-
oDrop. Eight A260 units were loaded onto a 10–50% su-
crose gradient obtained by adding 6 ml of 10% sucrose over
a layer of 6 ml 50% sucrose prepared in lysis buffer with-
out Triton and containing 0.5 mM DTT, in a 12-ml tube
(Polyallomer; Beckman Coulter). Gradients were obtained
with the help of a gradient maker (Gradient Master, Bio-
comp). Polysomes were separated by centrifugation at 35
000 rpm for 3 h using a Beckmann SW41 rotor. Eleven frac-
tions of 1 ml were collected while polysomes were moni-
tored by following the absorbance at 254 nm. Total pro-
tein was retrieved by 100% ethanol precipitation performed
overnight and analyzed by SDS-PAGE followed by western
blot.
35S Met/35S Cys labeling
HeLa eGFP andHeLa SDOS-eGFP cells seeded in a 6-well
platewere induced for 24 h andHeLa sh-GFPand sh-SDOS
for 48 h with 1 g/ml tetracycline. HCT116 were trans-
fected with an SDOS-directed siRNA. For control exper-
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iments, cells were transfected with a similar amount of non-
targeting control siRNA. Following proteins induction or
silencing, cells were incubated in cysteine/methionine-free
medium (Sigma-Aldrich) for 15 min followed by incubation
in cysteine/methionine-free medium containing 50 Ci/ml
35S-labeled cysteine/methionine (Perkin-Elmer) for 30 min.
Cells were then washed with PBS and lysed. A total of 10
g of total protein extract was analyzed by SDS-PAGE and
autoradiography.
PNK assay
Cells expressing eGFP-fusion proteins wereUV-crosslinked
on ice (150 mJ/cm2), lysed (100 mM KCl; 5 mM MgCl2,
10 mM Tris pH 7.5, 0.5% NP40; 1 mM DTT; protease
inhibitor cocktail) and homogenized passing the lysate
through a narrow needle (22G) followed by pulsed ultrason-
ication (3 × 10 s, 50% amplitude, on ice). Cleared lysates
were treated with 50 U/ml DNAseI (Takara) and RNa-
seI for 15 min at 37◦C, and used for immunoprecipitation
with GFP-Trap A agarose beads (Chromotek) for 2 h at
4◦C. Beads were washed four times with High salt buffer
(500 mM NaCl, 20 mM Tris pH 7.5, 1 mM MgCl2, 0.05%
NP40, 0.1%SDS, complete) and two timeswith PNKbuffer
(50 mM Tris pH 7.4, 50 mM NaCl, 10 mM MgCl2, 0.5%
NP40, 5 mM DTT). RNA crosslinked to the tagged RBP
is identified by radiolabeling with 0.1 Ci/l  -32P ATP
by T4 polynucleotide kinase (1 U/l) in PNK buffer (50
mMNaCl, 50 mM Tris pH 7.5, 0.5% NP40, 10 mMMgCl2
and 5 mM DTT) for 15 min at 850 rpm and 37◦C. Beads
were washed four to six times with PNKbuffer and protein–
RNA complexes were eluted by boiling samples 5 min at
95◦C. Samples were analyzed by SDS-PAGE and autora-
diography. For Flag-HA fusion proteins expressing cells the
protocol described in (14) was followed.
Interactome capture for eGFP-tagged proteins
1 × 15 cm plate of eGFP-fusion protein expressing cells
was induced for 24 h (TRAP1) and 16 h (SDOS, NUDT16
and eGFP) with 1 g/ml doxycycline. TRAP1-eGFP and
SDOS-eGFP cells were treated with 100 M 4-thiouridine
overnight and photoactivatable ribonucleoside-enhanced
crosslinked (PAR-CL) on ice at 0.60 and 0.30 J cm−2 with
UV light at 365 nm. Following UV-irradiation the protocol
was performed as previously described (15).
Individual nucleotide crosslinking and immunoprecipitation
(iCLIP)-seq
1 × 15 cm plate of eGFP-fusion protein expressing cells
was induced for 16 h with 1 g/ml doxycycline. Cells were
treated with 100 M 4-thiouridine overnight and photoac-
tivable ribonucleoside-crosslinked on ice at 0.60 and 0.30 J
cm−2 with UV light at 365 nM. Immediately after irradia-
tion, cells were lysed in 1 ml of lysis buffer (NaCl 100 mM,
MgCl2 5mM, Tris pH 7.5 10 mM, NP40 0.5%, SDS 0.1%,
Na deoxycholate 0.5%, DTT 1 mM (fresh), 1× AEBSF
(fresh). The cell lysate was passed three times through 27
1/2G needle and sonicated using a bioruptor (Digenode)
for three cycles of 10 s (pause 15 s), level M at 4◦C, then
it was cleared by centrifugation at 17 900 g for 10 min at
4◦C. RNA was then partially digested by adding 10 l of
1:100 dilution of RNase I (Ambion, AM2295), as well as
2 l of Turbo DNase (Ambion, AM 2238). After 3 min of
incubation at 37◦C under shaking at 1100 rpm 11 l of Ri-
bolock (Invitrogen) were added to each lysate. The lysates
were precleared by incubation with 50 l of equilibrated
control agarose beads (Thermo Scientific) for 30 min at 4◦C
under gentle rotation. eGFP-fusion proteins were then cap-
tured from precleared lysates by incubation with 40 l of
GFP-Trap agarose beads (GFP-Trap A, Chromotek) per
ml of lysate for 2 h, 4◦C, gentle rotation. Beads were col-
lected by centrifugation and washed twice with High salt
buffer (NaCl 500 mM, Tris–HCl pH7.5 20 mM, MgCl2 1
mM, NP40 0.05%, SDS 0.10%, 1× AEBSF (fresh)); twice
with Medium salt buffer (NaCl 250 mM, Tris–HCl pH7.5
20mM,MgCl2 1mM,NP40 0.05%, 1×AEBSF (fresh)) and
twice with Low salt buffer (NaCl 150 mM, Tris–HCl pH 7.5
20 mM, MgCl2 1 mM, NP40 0.01%, 1× AEBSF (fresh)).
The RNA was dephosphorylated, and 3′-linker ligated as
described in (16). The protein/RNA complexes were iso-
lated as described in (17). Samples were processed for sub-
sequent steps as described in (16). cDNA libraries obtained
after PCR amplification with universal Solexa primers (25
cycles) were multiplexed and sequenced using an Illumina
Next-generation sequencing platform at Science for Life
Laboratory at Karolinska Insitue, Solna, Sweden.
The data is publicly available at theGene ExpressionOm-
nibus (GEO) database under ID GSE118050.
Gene expression profile assay
Total RNA from SDOS-eGFP and control eGFP HeLa
cells was extracted using TRIzol reagent (Invitrogen) after
24 h of induction with Tetracycline (1 g/ml).
RNA concentration was evaluated with a NanoDrop
2000c spectrophotometer (Thermo Scientific), its quality
was assessed with a Bioanalyzer 2100 (Agilent Technolo-
gies). For each sample, 300 ng of total RNA were reverse
transcribed and used for synthesis of cDNA and biotiny-
lated cRNA according to the Illumina TotalPrep RNA am-
plification kit protocol (Ambion). A total of 750 ng of each
cRNA were hybridizated on Illumina HumanHT12 v4.0
Expression BeadChip array (Illumina); staining was per-
formed according to standard protocol supplied by Illu-
mina. BeadChip was dried and scanned with an Illumina
HiScanSQ system (Illumina). Analysis was performed in
triplicate for each sample.
The data is publicly available at theGene ExpressionOm-
nibus (GEO) database under ID GSE118050.
RNA extraction and RT-qPCR analysis
Total RNA extraction was performed by using the TRI
Reagent (Sigma-Aldrich, product code T9424) following
the manufacturer’s instruction. For first-strand synthesis of
cDNA, 1 g of RNA was used in a 20-l reaction mix-
ture by using a SensiFast cDNA synthesis kit (Bioline). For
real-time PCR analysis, 0.4 l of cDNA sample was am-
plified by using the SensiFast Syber (Bioline) in an iCy-
cler iQReal-TimeDetection System (Bio-Rad Laboratories
GmbH, Segrate, Italy).
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The reaction conditions were 95◦C for 2 min followed by
40 cycles of 5 s at 95◦C and 30 s at 60◦C. Actin was used as
internal control. The full list of primers used is reported in
Supplementary Materials and Methods.
Ribosome profiling
Ribosome profiling was performed according to the pro-
tocol described in (18). Briefly, unfused eGFP and SDOS-
eGFP cells were cultured in 15 cm plates and induced with
doxycycline for 24 h. After 15 min incubation with 100
g/ml cycloheximide (Sigma-Aldrich; C4859) at 37◦C, cells
were washed with ice cold PBS and 1 ml of lysis buffer
(20 mM Tris–HCl pH 7.4, 150 mM NaCl, 5 mM MgCl2, 1
mMDTT, 100 g/ml cycloheximide, 1% Triton-X100) was
added. Cells were then collected and incubated on ice; glass
beads (Sigma-Aldrich; G8772) were added to the lysate and
cells were broken by vortexing at medium speed for 3 pulses
of 10 s. After 10 min of incubation on ice, lysates were cen-
trifuged for 10 min at 10 000 rpm at 4◦C and the super-
natant was recovered. RNA was partially digested with 3.5
l of RNase I (100 U/l, Invitrogen AM2294) per 800 l
of lysate. After 15 min of incubation at 24◦C, lysates were
placed on ice and supplemented with 10 l of SUPERaseIn
(20 U/l, Invitrogen AM2694). Lysates were then loaded
on a 34% sucrose cushion (34% sucrose in 20 mM Tris–
HCl pH 7.4, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT
and 100 g/ml cycloheximide) and monosomes were pel-
leted by centrifugation for 1 h at 70 000 rpm using a Beck-
man TLA 100.3 rotor. RNA was extracted from the pel-
let and ribosome-protected fragments (RPFs) of 30 nt were
purified as described (18). RPFs were depleted of riboso-
mal RNA with the Ribo-Zero rRNA removal kit (Epicen-
tre MRZH116) according to manufacturer’s indications.
cDNA libraries were generated according to (18) and se-
quenced by Solexa using a HiSeq 2000, Single Read, 50 nt
at the CRG Genomics Core Facility, Barcelona, Spain.
The data is publicly available at theGene ExpressionOm-
nibus (GEO) database under ID GSE118050.
GFP-trap immunoprecipitation and RT-qPCR
1× 15 cm plate of SDOS-eGFP and eGFP control cells was
induced for 16 h with 1 g/ml doxycycline. SDOS-eGFP
cells were treated with 100 M 4-thiouridine overnight and
photoactivable ribonucleoside-crosslinked on ice at 0.30 J
cm−2 with UV light at 365 nM. eGFP cells were crosslinked
on ice at 0.15 J cm−2 with UV light at 254 nM. Immediately
after irradiation, cells were lysed in 1ml of lysis buffer (NaCl
100 mM, MgCl2 5 mM, Tris pH 7.5 10 mM, NP40 0.5%,
SDS 0.1%, Na deoxycholate 0.5%, DTT 1 mM (fresh), 1×
AEBSF (fresh), 100 U/ml Ribolock RNase inhibitor, 200
M ribonucleoside vanadyl complex). The cell lysate was
passed three times through 27 1/2G needle and sonicated
using a bioruptor (Digenode) for 3 cycles of 10 s (pause
15 s), level M at 4◦C, then it was cleared by centrifuga-
tion at 17 900 g for 10 min at 4◦C. A total of 50 l of in-
put were used to measure fluorescence signal at plate reader
in order to normalize the amount of eGFP proteins to be
immunoprecipitated. A total of 30 l of control magnetic
agarose beads (Pierce) and GFP-trap MA beads (Chro-
motek) were equilibrated in Dilution buffer (NaCl 500mM,
MgCl2 1mM, SDS 0.05%,NP40 0.05%, Tris pH 7.5 50mM,
100 U/ml Ribolock RNase inhibitor (fresh), 1× AEBSF
(fresh)). Lysates were pre-cleared for 30 min under rota-
tion at 4◦C with 30 l of control magnetic agarose beads.
GFP-trap MA were incubated with Escherichia coli tRNA
(1mg/ml) for 15min in dilution buffer under rotation at 4◦C
and then washed two times with dilution buffer. Pre-cleared
lysates were then incubated with GFP-trap MA beads for 2
h under rotation at 4◦C. Beads were then washed two times
with High salt buffer (NaCl 500 mM, Tris pH 7.5 20 mM,
MgCl2 1mM,NP40 0.05%, SDS 0.1%, Ribolock RNase in-
hibitor 100U/ml (fresh), 1×AEBSF (fresh) and three times
with Low salt buffer (NaCl 150 mM, Tris pH 7.5 20 mM,
MgCl2 1 mM, NP40 0.01%, Ribolock RNase inhibitor 50
U/ml). Beads were resuspended in 100 l of Proteinase K
buffer (NaCl 0.1M, Tris pH 7.5 10 mM, ethylenediaminete-
traacetic acid 1 mM, SDS 0.5%, 200 g/ml Proteinase K,
50 pg spike-in control RNA) and incubated at 55◦C for 1
h under constant mixing. To recover RNA, 100 l of TRI
Reagent were directly added to the buffer-containing beads
followed by extraction and ethanol precipitation. The RNA
was reverse transcribed, and the resulting cDNA was an-
alyzed by quantitative PCR. The amount of precipitated
RNA from immunoprecipitates (IPs) was normalized to the
amount of the spike-in control.
Confocal microscopy and analysis of the cilium
HeLa cells were seeded on coverslips, induced for 24
h (GFP/SDOS-GFP) or 48 h (shGFP/shSDOS), then
serum-starved for 48 h to induce the formation of the cil-
ium. Cells were then fixed with 4% (w/v) paraformaldehyde
in PBS for 20min, blocked and permeabilized with 0.4%
(w/v) BSA, 0.1% (v/v) Triton X-100, 5% (v/v) FBS in PBS
for 15min atRTbefore staining over night with alphaTubu-
lin (acetyl K40) antibody (ab179484, Abcam, Cambridge,
UK). Cells were then analyzed with a Leica TCS-SMD Sp5
confocal microscope by using Argon laser (488 nm) and
DPSS laser (561 nm). Single-cell analysis of cilia length (ex-
pressed in micron) was carried out by using LAS AF soft-
ware on maximal projection of at least 20 optical Z-slices of
0.5-micron-thick acquired with a 63 × 1.4 NA immersion
oil objective.
Bioinformatic analyses
Bioinformatic analyses of gene expression profiling, iCLIP
and Ribosome profiling, Gene Ontology (GO) are reported
in Supplementary Materials and Methods
RESULTS
SDOS and TRAP1 are protein partners
Preliminary results from our lab showed that TRAP1 in-
teracts with the poorly characterized protein SDOS. To
confirm and functionally characterize the potential inter-
action between SDOS and TRAP1, we generated HeLa
cell lines expressing either SDOS-eGFP or TRAP1-eGFP
in an inducible manner. eGFP fusion proteins were im-
munoprecipitated with the highly specific nanobody against
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Figure 1. SDOS and TRAP1 are protein partners. (A) Volcano plot showing SDOS (left) and TRAP1 (right) protein partners identified byMS (dark-red=
significant, light blue= intermediate, light gray= not significant). Relevant protein-partners (RPS28, SDOS, TRAP1, TP53BP1) are highlighted. (B) Silver
staining showing the pattern of SDOS-eGFP and TRAP1-eGFP IPs (specific band indicated with asterisk). (C) Co-immunoprecipitation of TRAP1 and
SDOS from HeLa cells following induction of TRAP1-eGFP and eGFP for 24 h. Total lysates were immunoprecipitated with GFP-Trap MA magnetic
agarose beads and analyzed by WB with the indicated antibodies. (D) Representative image of PLA showing the interaction of SDOS with TRAP1 in
HCT116 cells. Positive signals of interaction are shown as red dots, nuclei are stained with DAPI (blue). Negative control has been obtained by hybridizing
cells with TRAP1 antibody only. (E) Representative image of PLA showing the interaction of SDOS with rpS28 in HeLa cells, following induction of
SDOS-eGFP or unfused eGFP (negative control) for 24 h and hybridization with anti-GFP and anti-rpS28 antibodies. Positive signals of interaction are
shown as red dots, nuclei are stained with DAPI (blue). (F) Computational prediction of SDOS protein partners network using STRING database (https:
//string-db.org). Interactions include direct (physical) and indirect (functional) associations. Light-blue edge: known interaction from curated databases;
purple edge: experimentally determined interaction; green edge: textmining; black edge: co-expression; dark-blue edge: protein homology.
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eGFP (19) in presence of RNases and the eluates were an-
alyzed by label-free quantitative proteomics (Figure 1A).
The purity of SDOS and TRAP1 IPs was confirmed by sil-
ver staining (Figure 1B). Mass spectrometry revealed sev-
eral SDOS and TRAP1 interactors that were absent in
the unfused eGFP control (Tables 1 and 2). These pro-
tein partners are expected to bind directly to SDOS and
TRAP1 as the RNase treatment would disrupt any inter-
action mediated by RNA. The quality of our proteomic
results was highlighted by the identification of 53BP1 as
the primary interactor of SDOS, as previously described
(4). Strikingly, SDOS and TRAP1 were strongly enriched
in both SDOS-eGFP and TRAP1-eGFP immunoprecipi-
tations, demonstrating that they are high confidence inter-
action partners (Figure 1A). This interaction was further
confirmed by co-immunoprecipitation by isolating TRAP1-
eGFP and revealing endogenous SDOS, which is totally ab-
sent in the unfused eGFP IP (Figure 1C). We further visu-
alized TRAP1/SDOS interaction by in situ proximity lig-
ation assay (PLA) in HCT116 colorectal carcinoma cells.
Using specific antibodies against SDOS and TRAP1, PLA
revealed specific stained foci not only confirming their di-
rect interaction in living cells, but also indicating that such
interaction may occur in the cytoplasm (Figure 1D).
To determine whether SDOS–TRAP1 complex con-
tains other proteins, we searched in our proteomic dataset
for interactors common for both proteins (Tables 1 and
2). Interestingly, the ribosomal protein S28 (RPS28) was
the only protein present in both SDOS and TRAP1 im-
munoprecipitations, suggesting that SDOS may associate
with ribosomes as previously shown for TRAP1 (8,9).
The interaction between SDOS and rpS28 was validated
by PLA (Figure 1E). Out of the 39 interactors identi-
fied, 12 (31%) (TUBA1A, CCT2, CCT4, CCT5, CCT7,
CCT8, SLC25A4, HSPA5, HSPA8, PPP6R3, ANKRD28,
HDAC6) are present in the recently published mammalian
ribo-interactome (20). In addition, STRING network anal-
ysis of SDOS partners (21) highlighted an enrichment in
proteins involved in protein folding and de novo posttrans-
lational protein folding such as TRAP1, CCT4, CCT5,
CCT8, TUBA1A, TUBA4A (Figure 1F). The CCT com-
plex associates co- and post-translationally with approxi-
mately 5–10% of the newlymade proteins (22), aligning well
with the hypothesis of SDOS binding to ribosomes.
SDOS associates with actively translating polyribosomes
SDOS was first identified as a cytosolic protein involved in
the assembly of focal adhesions and actin stress fibres (2,3).
However, it has recently been shown that this protein also
localizes in the nucleus––like its paralogNUDT16p––where
it interacts with 53BP1 (4). In agreement with both stud-
ies, we confirmed that SDOS localizes in both nucleus and
cytoplasm (Supplementary Figure S1A).To get more in-
sights into the cytoplasmic localization of SDOS, we per-
formed cell fractionation experiments. WB analysis of sub-
cellular fractions of HeLa SDOS-eGFP revealed that a pro-
portion SDOS is present at the ER (Figure 2A). In agree-
ment, endogenous SDOSwas also identified in the ER frac-
tion (Supplementary Figure S1B). In agreement with pre-
vious data (7), beside the ‘canonical’ mitochondrial local-
ization, TRAP1 was found in the ER fraction (Figure 2A).
Since the distribution of both proteins only overlaps at the
ER, it is likely that the interaction between these two pro-
teins occurs at this compartment. To confirm this possibil-
ity, we performed a TRAP1 IP from the ER fraction and
observed that SDOS is co-isolated with TRAP1, suggesting
that both proteins interact at the ER (Figure 2B). Impor-
tantly, SDOS was not immunoprecipitated when TRAP1
was depleted with shRNAs, demonstrating that the anti-
body against TRAP1 does not cross-react with SDOS (Fig-
ure 2B).
SDOS localization at the ER and its interaction with the
ribosomal protein RPS28 (Table 1) suggest that it may as-
sociate with ribosomes, in analogy to its protein partner
TRAP1 (8,9). To test this hypothesis, we isolated ribosomal
fraction fromHCT116 total cell extracts. Analysis of the ri-
bosomal (ribo) and non-ribosomal (non-ribo) fractions by
WB demonstrated that both the endogenous SDOS and ec-
topically expressed myc-tagged SDOS associate with ribo-
somes (Figure 2C). To verify if the association of SDOS
with ribosomes might reflect a functional role in protein
synthesis, we performed a polysome profiling analysis in
SDOS-eGFP and unfused eGFP HeLa cells. Both endoge-
nous SDOS and ectopically expressed SDOS-eGFP co-
sediment with actively translating polyribosomes, whereas
unfused eGFP failed to do so (Figure 2D). Notably, asso-
ciation of SDOS with ribosomes is prevented by inhibiting
protein synthesis with puromycin, which causes disassembly
of active 80S ribosomes (Supplementary Figure S1C). Ac-
cordingly, a PLA using antibodies against phospho(active)-
ribosomal protein S6 and eGFP upon expression of SDOS-
eGFP HeLa cells showed intense staining at multiple cyto-
plasmic foci. These foci were virtually absent in the eGFP
control but also dramatically reduced in the SDOS-eGFP
cells upon translation arrest triggered by 1 h treatment with
cycloheximide (200 g/ml) (Figure 2E). In agreement, in-
hibition of protein synthesis by emetine or puromycin also
yields significant reduction in proximity ligation when using
antibodies against SDOS and p-rpS6 (Supplementary Fig-
ure S1D). Shorter (15 min) treatment with cycloheximide
100 g/ml, which is the concentration and incubation time
typically used in polysome profiling to prevent ribosomal
run-off, did not disrupt the interaction between SDOS and
p-rpS6 (Supplementary Figure S1D). This milder treatment
did not induce eIF2 phosphorylation, which is a marker
of translation initiation arrest, opposite to emetine or the
stronger cycloheximide treatment (Supplementary Figure
S1E). These data thus confirm that SDOS is present in the
ribosomal fraction and that this localization is dependent
on active protein synthesis.
SDOS affects protein synthesis
To verify if SDOS plays an active role in the regulation
of translation, we assessed protein synthesis by radioactive
labeling with [35S]-Met/Cys followed by autoradiography,
either upon overexpression or silencing of SDOS. SDOS-
eGFP cells incorporate less radiolabeled amino acids into
newly synthesized proteins than the cells expressing unfused
eGFP (Figure 3A). Conversely, the lack of SDOS caused the
opposite result, promoting higher rates of [35S]-Met/Cys in-
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Figure 2. SDOS localizes on the ER and associates with actively translating polyribosomes. (A) Subcellular fractionation of HeLa cells into mitochondrial
(Mito), cytosolic (Cyto) and microsomal (ER) fractions following 24 h induction of SDOS-eGFP. Total lysate and fractions were analyzed by WB with
indicated antibodies. BiP is used as a ER marker, GAPDH as a cytosolic marker and VDAC1 as a mitochondrial marker. (B) WB analysis of TRAP1-IP
from the ER fraction with SDOS, TRAP1 antibodies. Vinculin is used as internal control. (C) Ribosomal purification from HCT116 cells and HCT116
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Proteins from each fractionwere analyzed byWBwith the indicated antibodies. rpL3was used as a ribosomemarker, eIF4B and eIF4Ewere used asmarkers
of translation initiation complex. (E) Representative image of PLA showing the interaction of SDOS-eGFPwith phosphorylated (active) ribosomal protein
S6 (phospho-rpS6) in HeLa cells following 24 h induction of SDOS-eGFP by using GFP and phospho-rpS6 antibodies. Positive signals of interaction are
shown as red dots, nuclei are stained with DAPI (blue). Cycloheximide treatment (200 g/ml, 1 h) was used to confirm the causal role of active protein
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Figure 3. SDOS overexpression represses translation of specific mRNAs. (A) Autoradiography of total lysates from cells labeled with 35SMet/35S Cys (left)
and relative densitometric band intensities (right), calculated by assuming protein levels of the control equal 1, following 24 h induction of eGFP/SDOS-
eGFP or 48 h of shGFP/shSDOS in Hela FITR or transfection of SDOS-targeting siRNA and non-targeting control siRNA in HCT116 cells. The
P-value in the graph indicate the statistical significance based on one-sample t-test (n= 3). (B) WB analysis of total lysates following puromycin treatment
(1 g/ml, 15 min) (left) and relative densitometric band intensities (right), calculated by assuming protein levels of the control equal 1. The P-value in the
graph indicate the statistical significance based on one-sample t-test (n = 3).
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Table 1. SDOS interacting proteins obtained by label-free quantitative proteomics
Gene names Protein names
Significance (log10
t-test P-value)
Difference
(SDOS/eGFP log2
FC)
TP53BP1 Tumor suppressor p53-binding protein 1 8.25077 11.0722
CCT5 T-complex protein 1 subunit epsilon 7.1619 5.88357
DYNLL1; DYNLL2 Dynein light chain 1, cytoplasmic;Dynein light
chain 2, cytoplasmic
5.98194 7.46163
SLC7A5 Large neutral amino acids transporter small
subunit 1
5.66293 6.46204
CCT4 T-complex protein 1 subunit delta 5.64192 7.6541
SLC16A3 Monocarboxylate transporter 4 5.59991 4.88154
TUBA4A Tubulin alpha-4A chain 4.91233 4.91643
TUBB8 Tubulin beta-8 chain 3.99008 9.00189
TUBA1A; TUBA3C;
TUBA3E
Tubulin alpha-1A chain;Tubulin alpha-3C/D
chain;Tubulin alpha-3E chain
3.72152 7.84447
PPP6C Serine/threonine-protein phosphatase 6 catalytic
subunit
3.70021 3.92096
POLDIP2 Polymerase delta-interacting protein 2 3.53627 4.22019
SQSTM1 Sequestosome-1 3.4972 7.90479
ANKRD28 Serine/threonine-protein phosphatase 6 regulatory
ankyrin repeat subunit A
3.46259 4.00495
MIF Macrophage migration inhibitory factor 3.43102 5.75599
BAG2 BAG family molecular chaperone regulator 2 3.30518 6.02968
PPP6R3 Serine/threonine-protein phosphatase 6 regulatory
subunit 3
3.30512 4.82287
LGALS3BP Galectin-3-binding protein 3.08069 9.86244
TRAP1 Heat shock protein 75 kDa, mitochondrial 3.035 6.92604
TCEAL1 Transcription elongation factor A protein-like 1 2.82362 6.00085
HNRNPH3 Heterogeneous nuclear ribonucleoprotein H3 2.67817 6.1067
NUDT16 U8 snoRNA-decapping enzyme 2.61619 8.05465
RPS28 40S ribosomal protein S28 2.3294 4.91507
CCT8 T-complex protein 1 subunit theta 2.25142 6.83071
SLC25A10 Mitochondrial dicarboxylate carrier 2.20143 5.34728
USP11 Ubiquitin carboxyl-terminal hydrolase 11 2.17424 7.29486
LAMA1 Laminin subunit alpha-1 2.10802 4.40167
SLC25A6; SLC25A4 ADP/ATP translocase 3;ADP/ATP translocase 1 1.98901 5.70873
HDAC6 Histone deacetylase 6 1.84778 3.31599
SBSN Suprabasin 1.82849 4.65037
CPS1 Carbamoyl-phosphate synthase [ammonia],
mitochondrial
1.64454 5.035
CCT2 T-complex protein 1 subunit beta 1.63926 4.41436
CCT7 T-complex protein 1 subunit eta 1.54531 5.05293
S100A7; S100A7A Protein S100-A7;Protein S100-A7A 1.53909 5.10047
HAGH Hydroxyacylglutathione hydrolase, mitochondrial 1.39384 2.8948
HSPA8 Heat shock cognate 71 kDa protein 1.37934 6.06043
TOMM40 Mitochondrial import receptor subunit TOM40
homolog
1.32786 3.5971
SNRPA1 U2 small nuclear ribonucleoprotein A 1.30897 5.05506
HSPA5 78 kDa glucose-regulated protein 1.30267 5.11503
corporation in bothHeLa andHCT116 cells to a similar ex-
tent (Figure 3A). Taking together, these data indicate that
SDOS attenuates protein synthesis. To support these results,
we treated cells with puromycin, which binds to nascent
peptides and detected these newly synthesized polypep-
tides by WB with antibodies against puromycin. This ap-
proach yielded similar outcome to the [35S]-Met/Cys in-
corporation; i.e. overexpression of SDOS repressed trans-
lation, whereas SDOS silencing increased it (Figure 3B).
These data indicate that SDOS influences translation, pos-
sibly though a direct interaction with ribosomes.
SDOS is a novel RNA-binding protein
SDOS harbors a catalytically inactive NUDIX domain, but
it may retainRNA-binding activity (1). To evaluate whether
SDOS interacts with RNA in living cells, we performed
crosslinking and immunoprecipitation (CLIP) followed by
T4 polynucleotide kinase (PNK) assay. In brief, cells are ir-
radiatedwithUV light to promote protein–RNAcrosslinks,
and then RNA is trimmed by RNase treatment and the
protein–RNA complex is immunoprecipitated. The PNK
treatment incorporates a [32P] to the 5′ of the RNA remnant
crosslinked to the protein. Bands matching the molecular
weight of SDOS-eGFP and the positive control MOV10-
eGFP were detected by autoradiography in an UV and
RNase-dependent manner, while no signal was observed
in the eGFP immunoprecipitation (Figure 4A). This indi-
cates that SDOS interacts with RNAs in living cells. No-
tably, the same results were obtained with a different tag
(SDOS-Flag-HA) (Figure 4B). Considering that SDOS is a
paralog of the RNA decapping enzyme NUDT16, it is con-
ceivable that SDOS RNA-binding capacity could be under-
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Figure 4. SDOS is a RBP. (A and B) Autoradiography and WB analysis of eGFP-fused (A) and Flag-HA tagged (B) proteins after PNK assay in the
presence of increasing concentration of Rnase I (panel A: 1, 10, 50, 100 ng/l; panel B: 1, 10, 100 ng/l). MOV10-YFP was used as positive control.
Unfused eGFP and M2-Flag beads were used as negative control, respectively. Asterisks on autoradiography indicate specific bands. (C) eGFP-based
RNA-binding assay with schematic representation of the procedure (left) and relative green fluorescence signal of RNA-bound fraction over input from
cells expressing different eGFP fusion proteins (right). Numbers above bars indicate the statistical significance (P-value), based on one-sample t-test (n =
3). (D) BindUP RNA-binding surface prediction of SDOS (PDB ID: 3kvh). The most likely RNA-binding surfaces are represented in blue and orange,
while the NUDIX domain is represented in red. (E) Electrostatic surface potential of SDOS. The protein surface is represented according to charge.
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Table 2. TRAP1 interacting proteins obtained by label-free quantitative proteomics
Gene names Protein names
Significance
(log10 t-test P-value)
Difference
(SDOS/eGFP log2
FC)
ABCF2 ATP-binding cassette sub-family F member 2 2.68385 14.2995
TOMM40 Mitochondrial import receptor subunit TOM40
homolog
3.88582 11.2559
ACAT1 Acetyl-CoA acetyltransferase, mitochondrial 3.97718 8.15674
HSP90AB1 Heat shock protein HSP 90-beta 2.50603 6.42103
CPS1 Carbamoyl-phosphate synthase [ammonia],
mitochondrial
1.90015 6.23542
ACTA1; ACTC1;
ACTG2; ACTA2
Actin, alpha skeletal muscle;Actin, alpha cardiac
muscle 1;Actin, gamma-enteric smooth
muscle;Actin, aortic smooth muscle
1.71572 6.06877
HIST1H1B Histone H1.5 1.94157 5.88322
MIF Macrophage migration inhibitory factor 6.19998 5.29286
SNRPA1 U2 small nuclear ribonucleoprotein A 1.34302 5.17618
SBSN Suprabasin 1.93546 5.10971
NUDT16L1 Protein syndesmos 3.22837 4.57307
S100A7; S100A7A Protein S100-A7;Protein S100-A7A 1.31531 4.29323
POLDIP2 Polymerase delta-interacting protein 2 2.61116 3.89041
RPS28 40S ribosomal protein S28 2.64818 3.7948
GHITM Growth hormone-inducible transmembrane protein 1.65522 3.29815
estimated if SDOS binds to the 5′ cap structure, which can-
not be phosphorylated by PNK. To further validate SDOS
RNA-binding activity with an orthogonal approach, we
used RNA-interactome capture (RNA-IC) (11,23). In brief,
RNA-IC also employs UV crosslinking of cultured cells
expressing SDOS-eGFP recombinant protein, but in this
case the RBP is isolated by hybridization of the poly(A) tail
present in the target RNA with oligo(dT) magnetic beads,
via stringent washes. The presence of the eGFP-fusion pro-
tein in the eluates is detected by fluorescence using a plate
reader (Figure 4C) (14). Importantly, we detected signif-
icant green fluorescence in eluates from the cells express-
ing SDOS-eGFP as well as the positive control hnRNPC-
eGFP, awell-known canonical RBP, while no signal was ob-
served in the negative control (eGFP) (Figure 4C). It is im-
portant to mention that hnRNPC crosslinks with RNA be-
tween 10 and 100 times more efficiently than the majority of
well-established RBPs (11,14,15). By using these two com-
plementary approaches, we demonstrate that SDOS binds
RNA in living cells, thus providing the first evidence that
SDOS is a novel RBP. To predict the most likely RNA-
binding surface within SDOS, we used BindUP software
(24), which calculates the local electrostatic potential to pre-
dict protein surfaces compatible with RNA binding (Figure
4D and E). BindUP identified two large positively charged
patches as candidates for mediating the interaction with
RNA (Figure 4D, blue and orange). Interestingly, the re-
gion compatible with RNA binding in SDOS is also present
in NUDT16 (Supplementary Figure S2A and B). As a con-
sequence RNA-binding activity of NUDT16 and SDOS to
RNA, measured by RNA-IC, is comparable (Supplemen-
tary Figure S2C). The amino acids forming the patches pre-
dicted by BindUP are listed in Supplementary Table S1.
Identification of the RNAs bound by SDOS
To determine the pool of RNAs bound by SDOS, we per-
formed individual nucleotide resolution CLIP followed by
sequencing (iCLIP-seq). We obtained a set of 4456 SDOS
target RNAs identified in three biological replicates (Sup-
plementary Table S2). The vast majority (66%) of theRNAs
bound by SDOS are protein-coding transcripts (mRNAs,
Figure 5A), while only 8% correspond to long intergenic
non-coding RNAs (lincRNAs). Most of the reads (69%)
mapped to introns, but also coding regions (9%), 3′UTRs
(13%) and 5′UTR (5%) (Figure 5B and D). While a decap-
ping enzyme is expected to bind mostly to 5′ UTRs (25), the
preferential binding of SDOS to other mRNA regions sug-
gests that the sequence alterations compared to NUDT16
have profound consequences in its binding potential. Inter-
action with introns is likely mediated by the nuclear SDOS
pool andmay have consequences in RNA splicing. In agree-
ment with this idea, our protein–protein interaction analy-
sis revealed that SDOS interacts with HNRNPH3 (Table
1), which is localized in nuclear bodies and is involved in
splicing (26). Analysis of enriched motifs sequence motifs
around the strongest 10% of SDOS binding sites revealed a
preference for C-rich sequences (Figure 5C and Supplemen-
tary Figure S3). SDOS has been reported to form homo-
dimers (4,27,28), and adjacent C-rich motifs may reflect co-
binding for two SDOS proteins to same RNA (Supplemen-
tary Figure S3).
GO analysis of the SDOS-bound mRNA network shows
enrichment in pathways involved in focal adhesion and
actin cytoskeleton organization, i.e. ‘Rap1-signaling path-
way’, ‘focal adhesion’, ‘regulation of actin cytoskeleton’ and
‘MAPK signaling pathway’, among the top 10 enriched bio-
logical processes (Figure 5E). This agrees with earlier stud-
ies reporting a direct role of SDOS in development of fo-
cal adhesions (2,3). Notably, the top three enriched biolog-
ical processes are ‘metabolic pathways’, ‘pathways in can-
cer’ and ‘PI3K-Akt signaling pathway’ (Figure 5E). This is
in agreement with suggested role of SDOS in cancer (4,29),
PI3K-Aktmediated cellular processes being among the cru-
cial mechanisms in tumour development (30) and consider-
ing that emerging evidence support the definition of cancer
as a metabolic disease (31). Remarkably, some SDOS RNA
targets are linked to neurological disorders and ciliopathies
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Figure 5. SDOS binds RNAs in multiple regions. (A and B) Genomic location of nucleotides crosslinked to SDOS. Pie charts depicts assignment by class
(A) or feature (B) of RNA bound, as given on the right. (C) Logos for two enriched sequences around ±12 bp of 448 strongest SDOS binding sites. (D)
Conversion of mapped iCLIP sequence reads into cDNA count values for Tmem107, Aifm1 and Linc00324. (E and F) GO analysis showing the top 10
biological pathways (E) and the top 10 diseases (F), whose associated mRNAs are enriched in the iCLIP dataset.
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such as Joubert syndrome, Retinitis pigmentosa, Primary
ciliary dyskinesia (Figure 5F). Ciliopathies are a group of
developmental and degenerative diseases that affect virtu-
ally all organs and tissues and are commonly caused by de-
fects in primary cilia formation or function (32). Therefore,
SDOS may be involved in the expression of numerous rele-
vant genes with direct links to disease.
Identification of transcripts translationally regulated by
SDOS
Different lines of evidence suggest that SDOS plays a role
in translation: (i) SDOS interacts with TRAP1 and RPS28
at the ER (Figures 1 and 2), (ii) it co-sediments with ribo-
somes (Figure 2 and Supplementary Figure S1) perturba-
tion of SDOS causes alterations in protein synthesis (Fig-
ures 3 and 4) SDOS is an RBP that interacts with numer-
ous mRNAs (Figure 4). To determine whether perturbation
of SDOS causes alterations in RNA levels, and if such al-
terations could cause the changes in protein synthesis rate
detected upon SDOS up- or downregulation, we employed
a microarray analysis upon SDOS-eGFP overexpression in
HeLa cells (Supplementary Table S3). The quality of the
microarray analysis was confirmed by RT-qPCR, showing
significant regulation of 10 out of 14 mRNAs with differ-
ential expression in SDOS-eGFP detected by microarrays
(Supplementary Figure S4A). GO analysis of the mRNAs
with reduced abundance in cells overexpressing SDOS re-
vealed enrichment in the GO terms ‘cytoplasmic transla-
tion’, ‘translational termination’, ‘large ribosomal subunit’,
‘structural constituent of ribosomes’ and ‘mitochondrial
translation’ (Figure 6A). This indicates that SDOS could,
additionally, regulate translation indirectly influencing the
abundance of mRNAs encoding ribosomal proteins. On the
other hand, the mRNAs with increased abundance after
SDOS overexpression are enriched inGO terms ‘nucleus lo-
calized genes’ and ‘centrosome cycle’, which agrees with the
existence of a nuclear population of SDOS and the discov-
ered link between SDOS and cilia-linked genes, respectively
(Figure 6A), considering that the primary cilium originates
from the centrosome and is coordinated with the cell cy-
cle (33). However, only 23 up- and 56 downregulated RNAs
showed a 1.5 < fold change > 0.75, suggesting that mRNA
abundance is not the main determinant of the translation
attenuation caused by SDOS overexpression.
To directly identify those transcripts whose transla-
tion may be affected by SDOS, we performed ‘ribosome
profiling and sequencing’ (RP-seq) after SDOS overex-
pression. This technique identifies the RNA regions pro-
tected by ribosomes from RNase cleavage leaving ribosome
footprints (i.e. ribosome-protected fragments, RPF) in a
transcriptome-wide manner (18). We identified 2058 mR-
NAs (ribosome profiling) (Supplementary Table S4) differ-
entially translated in SDOS-eGFP versus eGFP cell lines.
Interestingly, only 79 of these mRNAs displayed differen-
tial expression (RNA abundance) with P < 0.05, indicat-
ing that SDOS has little effects on RNA synthesis and
stability, while it is evidently involved in translation. Out
of the 2058 translationally regulated mRNAs, 690 (33.5%)
were upregulated, while 1368 (66.5%) were downregulated
(Figure 6B), further supporting the role played by SDOS
in translation repression. Regulated mRNAs are enriched
for transcripts encoding for proteins localized to midbody,
chromatin, nuclear speckle, nucleolus, cytosol andGolgi ap-
paratus. Speckles are membrane-less cellular compartment
where splicing factors accumulate. Therefore, SDOS may
regulatemRNA splicing directly (i.e. through direct binding
to introns, as suggested by the binding to intronic regions of
the transcripts and by the presence, in the proteomic analy-
sis of protein partners of HNRNPH3, which is involved in
the splicing process) or/and indirectly (i.e. through transla-
tional regulation of mRNAs encoding splicing factors).
To determine the scope of mRNAs identified by both
iCLIP and ribosome profiling, which are thus bound by
SDOS and regulated at a translational level, we cross-
referenced the iCLIP and the ribosome profiling datasets.
A subset of 399 mRNAs was present in both datasets and
we considered these as ‘direct’ targets, since they are both
bound by SDOS and regulated at translation (Supplemen-
tary Table S5). These transcripts were mainly translation-
ally repressed in SDOS-eGFP expressing cells (241 out of
399 mRNAs, 60.4%). Conversely, 158 mRNAs were trans-
lationally upregulated (39.6%). GO analysis of these di-
rect targets showed enrichment for ciliary transition zone
and kinesin complex (which is involved in cilium biogene-
sis) among the cellular component associated terms (Figure
6C). Ciliopathy-associated genes and cilia and centrosome
associated genes found in the ‘direct target’ list are reported
in Figure 6D and E. Among them, Tmem67, Cc2d2a and
Kif7mRNAs were linked to Joubert syndrome and Meckel
Gruber syndrome, both belonging to the ciliopathy family.
Mutation or dysregulation of Cc2d2a, Tmem67, Kif7 plus
Tmem107 and Topors, are known to cause ciliopathies (34).
Taken together, these analyses strongly suggest that SDOS
is involved in the regulation of primary cilia assembly.
SDOS interaction with mRNAs is involved in primary cilia
formation
We selected a subset of 11 candidate mRNAs identified
by iCLIP and ribosome profiling and involved in cilia for-
mation or/and ciliopathies, for further validation. Among
those, only Kif7 was upregulated in RT-qPCR experiments
(ß-actin was used as the internal control, as neither its lev-
els are affected by SDOS nor it is bound by SDOS) (Fig-
ure 7A). None of the other cilia-related mRNAs found in
the SDOS iCLIP were affected by SDOS overexpression
(Figure 7A and Supplementary Figure S4B). We then fo-
cus our attention on Cc2d2a, Tmem107 and Kif7 and con-
firmed by RNA immunoprecipitation (RIP) that mRNAs
are bound by SDOS, as they were significantly enriched in
SDOS-eGFP IPs over the eGFP negative control (Figure
7B). As expected, no enrichment was observed for the con-
trol ß-actin mRNA, which is not a SDOS mRNA target
according to the iCLIP data. Although Kif7 mRNA lev-
els were increased by SDOS-eGFP overexpression by nearly
2-fold (Figure 7A), it was enriched by 30-fold in the IPs,
confirming that Kif7 mRNA is also bound by SDOS (Fig-
ure 7B). Finally, we performed WB analyses to determine
whether SDOS perturbation affects protein expression of
cilia-linked transcripts, as indicated by ribosome profiling
(Figure 7C). AHI1 and TMEM107 fully confirmed RP-seq
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Figure 6. SDOS iCLIP and RP show common transcripts. (A) GO analysis showing the top 10 over- (green) and under- (red) represented significant
biological pathways associated to GE data. (B) Pie chart representing the ratio between up- and downregulated mRNAs according to RP-Seq analysis
following SDOS-eGFP overexpression. (C) GO analysis showing the top 10 significantly enriched cellular component terms associated to targets common
to both iCLIP and RP data. (D) Ciliopathy-associated genes found among the RP and iCLIP common targets according to Advaita Bio’s iPathwayGuide
analysis. (E) Cilia and centrosome-associated genes from RP and iCLIP common targets according to Advaita Bio’s iPathwayGuide cellular component
analysis.
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article/46/22/12067/5107578 by guest on 10 August 2020
12082 Nucleic Acids Research, 2018, Vol. 46, No. 22
-A
CT
IN
β TM
EM
10
7
CC
2D
2A KI
F7
0
1
2
3
10
20
30
40
R
N
A
 e
nr
ic
hm
en
t
in
 S
D
O
S
-e
G
FP
 IP
25
48
63
48
17
20
100
150
100
sh
-G
FP
sh
-S
DO
S
eG
FP
SD
OS
-e
GF
P
β-ACTIN
TMEM67
TMEM107
AHI1
SDOS
eGFP
A B
C D
TM
EM
10
7
CC
2D
2A KI
F7
0
1
2
3
0.8863 0.4281
0.0130
R
el
at
ive
 e
xp
re
ss
io
n
up
on
 S
D
O
S
-e
G
FP
 o
ve
re
xp
re
ss
io
n
KIF7150
AH
I1
KI
F7
TM
EM
67
TM
EM
10
7
AH
I1
KI
F7
TM
EM
67
TM
EM
10
7
0.0
0.5
1.0
1.5
2.0
2.5 SDOS-eGFP shSDOS
0.02
0.86
0.22
0.03 0.04
0.39
0.02
0.05
R
el
at
iv
e 
de
ns
ito
m
et
ric
ba
nd
 in
te
ns
ity
Figure 7. SDOS binds and regulates translation of mRNAs encoding for ciliary components. (A) RT-qPCR of Cc2D2a, Kif7 and Tmem107mRNAs from
HeLa cells upon 24 h of SDOS-eGFP or eGFP induction (Actin used as the internal control). Data are expressed asmean± S.E.M. from four independent
experiments with technical triplicate each. Numbers above bars indicate the statistical significance (P-value), based on one-sample t-test. Red line indicates
expression level of the relative eGFP control. (B) Representative results of RT-qPCR from RIP independent experiments to validate iCLIP data. RNA
enrichment was normalized to a spike-in control (red line). Actin was used as negative control showing no enrichment. (C and D) WB analysis of HeLa
cell extracts following SDOS-eGFP or eGFP (24 h) and sh-GFP or sh-SDOS (48 h) induction (C), with relative densitometric analysis (D), calculated by
assuming protein levels of the control equal 1. The P-value in the graph indicate the statistical significance based on one-sample t-test (n = 3).
data. Indeed, the levels of TMEM107 after SDOS-eGFP
overexpression were lower than in the eGFP control, while
the opposite outcome was observed for AHI1. Accordingly,
both TMEM107 and AHI1 levels were inversely regulated
upon SDOS silencing. Although RP-seq showed transla-
tional regulation of Kif7 mRNA upon SDOS overexpres-
sion, we could not detect changes in protein levels by WB,
which may be due to high stability or compensatory mech-
anisms. TMEM67 protein levels were also unaffected by
SDOS overexpression; however, SDOS silencing resulted in
an increased expression of TMEM67, confirming the trans-
lational impact detected with RP-seq (Figure 7D).
Since SDOS regulates several mRNAs involved in the
biogenesis of the primary cilium, we hypothesized that per-
turbation of SDOS may alter cilium formation. To ad-
dress this, cells overexpressing (Figure 8A) or lacking (Fig-
ure 8B) SDOS were serum deprived for 48 h to induce
the formation of primary cilia. Cilia were then stained by
acetylated tubulin antibodies and their length was mea-
sured by confocal microscopy analysis (Figure 8C). Al-
though length of primary cilia is highly variable between
cells and is influenced by several factors (35), we strikingly
found that SDOS silencing significantly increased average
cilium length, while SDOS overexpression reduced it (Fig-
ure 8C). Moreover, lack of SDOS led to a higher percent-
age of cilium-presenting cells than in control cells following
starvation, whereas SDOS overexpression reduced it (Fig-
ure 8D). These data confirm that SDOS controls cilia for-
mation.
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Figure 8. SDOS expression alters cilium formation. (A) Representative image of the primary cilium (red) and its length in HeLa cells upon overexpression
of SDOS-eGFP or the respective eGFP control. Cilium formation has been induced by serum starvation (48 h), then cells have been fixed, permeabilized
and hybridized with Acetyl-Tubulin as a primary cilium marker. Nuclei are stained with DAPI (blue). Scale bar: 15 M. (B) Representative image of the
primary cilium (green) and its length in HeLa cells upon induction of SDOS-directed shRNA and the respective shGFP control. Cilium formation has
been induced by serum starvation (48 h), then cells have been fixed, permeabilized and hybridized with Acetyl-Tubulin as a primary cilium marker. Nuclei
are stained with DAPI (blu). Scale bar: 15 M. (C) Length of primary cilia measured by confocal microscopy analysis of Acetyl-Tubulin-stained HeLa
cells upon SDOS overexpression (SDOS-eGFP, n = 146) or silencing (shSDOS, n = 110) and relative eGFP (n = 165) and shGFP (n = 168) controls.
Numbers indicate the statistical significance (P-value) based on the Student’s t-test. (D) Bar graph representing the percentage of ciliated HeLa cells upon
SDOS silencing (shSDOS) or overexpression (SDOS-GFP) compared to the respective shGFP and eGFP controls.
DISCUSSION
Using a multiple orthogonal methods we have shown that
the poorly characterized protein SDOS is a novel RBP that
regulates numerous mRNAs at the translational level and
plays a central role regulating cilia formation. Our iCLIP
data suggests that SDOS has a strong preference for C-rich
sequences, commonly CCCA (Figure 5 and Supplemen-
tary Figure S3). Most sequence-specific interactions with
RNA involve binding to the nucleotide bases (36). Since
UV crosslinking is mediated by the nucleotide bases (37),
SDOS-RNA crosslinking reflects direct contacts between
amino acids and bases placed at ‘zero’ distances. This phe-
nomenon is illustrated by the RBDmap experiments, where
the alpha-helix of the DEAD-box helicase fold contact-
ing the nucleotide bases crosslinks to RNA, while the do-
main regions interacting with the sugar-phosphate back-
bone failed to do so (14). Furthermore, the patch detected
by BindUP in SDOS as putative RNA-binding surface does
not only contain amino acids with potential to establish
electrostatic interactions with the phosphate-backbone (i.e.
R and K), but also aromatic (e.g. W, H, F) and hydrophilic
residues (e.g. T, S, N, D, E) with capacity to stack and to
form hydrogen bonds, respectively (36). Hence, SDOS has
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the potential to establish specific interactions with RNA,
although future structural analyses are required to visual-
ize the spatial arrangement between amino acids and ri-
bonucleotides in these interactions. Indeed, we demonstrate
that SDOS interacts with a subset of transcripts enriched
in mRNAs encoding for centrosomal proteins and com-
ponent of the primary cilium, and regulates their trans-
lation. Cilia are a sensory appendage that are present in
most mammalian cells and plays critical roles in signaling
pathways and cell-cycle progression. Mutation or dysregu-
lation of several of these genes are linked to rare diseases
called ciliopathies, a group of developmental and degenera-
tive diseases that affect almost all organs and tissues (34).
Indeed, we have found several genes crucially related to
the development of various ciliopathies as mRNA bound
and/or regulated at translation by SDOS. Among those,
Kif7, a cilia-associated protein belonging to the kinesin fam-
ily, whose genetic mutations have been associated with var-
ious ciliopathies; Ahi1, which is required for ciologenesis
and whose mutations cause specific forms of Joubert syn-
drome; Tmem67, which is required for ciliary structure and
function and whose genetic defects cause Meckel syndrome
and Joubert syndrome; Tmem107, which regulates ciliogen-
esis and ciliary protein composition and whose mutations
cause different ciliopathies, including Meckel–Gruber syn-
drome and orofaciodigital syndrome; Cc2d2a, which plays
a critical role in cilia formation and whose mutations cause
Meckel syndrome and Joubert syndrome (32,34).
For a long time, SDOS has been a protein with elusive
functional role and poor characterization, and only recently
it has been demonstrated that SDOS is a critical regula-
tor of the DSB repair pathway (4). Initially, SDOS was re-
ported to be involved in the regulation of cell migration, ei-
ther through its binding to the cytoplasmic domain of Syn-
decan 4 (2) or to the focal adhesion adaptor protein Pax-
illin (3). Interestingly, Paxillin localizes at the base of pri-
mary cilia next to the basal body inmammalian ciliated cells
(38). Syndecan itself has multiple connections with the non-
canonical Wnt pathway, an ancient and evolutionarily con-
served pathway that is crucial for regulation of cell fate de-
termination,migration and polarity (39). TheWnt pathway,
in turn, is dysregulated in the ciliopathies due to disruption
of physiological role of the primary cilium, a pivotal trans-
ducer of extracellular signals through this pathway (40). In
this context, our study provides evidence for a link between
the diverse SDOS functions. Notably, besides Wnt, many
of the signaling systems that control cell migration, another
function previously associated to SDOS (2,3), are also co-
ordinated by primary cilia, such as Hh, TGF and RTK
signaling (41–44). Relevant to the connection between the
newly discovered functions of SDOS in the regulation of
DSB repair and cilium biogenesis, an emerging area of re-
search claims the involvement of cilia and centrosomal pro-
tein in DNA damage response (DDR) mechanisms. Cilia,
centrosomes and the DDR are linked in several ways: (i)
the DDR pathway functions at the centrosome, (ii) ciliopa-
thy proteins function in the nucleus during DDR and (iii)
DDR and cilia share common regulatory proteins (45). One
of these is ATMIN, a co-factor for ATM in the response
to DNA damage (46) and also a transcriptional regulator
of ciliary dynein, DYNLL1 (47). Intriguingly, this protein
was found in our MS analysis of SDOS protein partners.
Moreover, ATM is the factor responsible for the dissocia-
tion of the SDOS–53BP1 complex, necessary for the sub-
sequent binding of 53BP1 to the effector proteins during
DDR (4).
Asymmetric localization of proteins can be achieved by
mRNA localization coupled to protein synthesis at a distal
site (48); however, cilia have no protein synthesis machin-
ery, therefore all protein components for the cilium needs
to be synthesized within the cytosol and then imported into
the cilium (49). Remarkably, this is consistent with our find-
ing that SDOS localizes to the rough ER and associates
with actively translating ribosomes to control synthesis of
constituent proteins of the primary cilium. In addition, our
iCLIP and ribosome profiling analyses indicated an enrich-
ment in transcripts involved inmetabolic pathways. Intrigu-
ingly, both cilia defects (50) and metabolic dysfunction (51)
have already been linked to cancer. In this view, the interac-
tion between SDOS and the molecular chaperone TRAP1
at the ER, where they regulate protein synthesis in a likely
cooperative manner, could contribute to the gene expres-
sion changes required by the metabolic rewiring in can-
cer cells, where TRAP1 plays a pivotal role in determin-
ingmetabolism-driven cancer development and progression
(52–55).
In conclusion, our study shows new functions and phys-
iological roles of a newly identified RBP SDOS in regulat-
ing cilia formation and suggests potential uncharacterized
links with novel developmental and degenerative diseases.
Future studies in cancers and cilia-related congenital disor-
ders are required to elucidate potential clinical relevance of
the promising novel biomarker SDOS, and SDOS/TRAP1
cooperation, in these pathological conditions.
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